No abstract was published with this document — society guidelines, consensus pathways, and scientific statements are typically released without one. See the Key Points and the linked PDF for the full content.
“We developed a standardized vocabulary for documenting and reporting critical cardiovascular adverse events, along with specifications for the exchange of that information between computer systems. The key use will be in reporting findings to the FDA, whether in the context of clinical trials, pharmacovigilance, or device surveillance. Ultimately, we anticipate widespread adoption of this vocabulary throughout healthcare (including routine clinical care) as a catalyst for accelerating improvements in patient management and treatment.”
Hicks et al. (2014) studied this question.